AASLD News

ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) and the American Society of Transplantation (AST) are pleased to announce the latest Practice Guideline on Adult Liver Transplantation: Diagnosis and Management of Graft-Related Complications published in Liver Transplantation , the premier journal equipping clinicians and researchers with the latest insights

The American Association for the Study of Liver Diseases (AASLD) applauds the U.S. Food and Drug Administration’s (FDA) recent approval of Wegovy®, widely recognized for weight loss and diabetes management, as a new treatment for adults with Metabolic dysfunction-Associated Steatohepatitis (MASH) and moderate to advanced liver fibrosis. MASH, a subset of Metabolic dysfunction-Associated Steatotic

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society funding source for liver disease research and training in the United States, announced today a funding commitment of over $1.7 million for over 150 grantees. This investment will fuel innovative research to advance the understanding, prevention, diagnosis, and treatment of

Incoming Councilor (2026-2031) Incoming Treasurer (2026-2028) For more information on the new leadership and to view the candidates for Councilor at Large, Chair Ethics Committee, and the 2026 Nominating Committee, please click here .

AASLD is pleased to announce the selection of thirty-seven hepatology leaders as Fellows and four allied health leaders focused on hepatology as Associate Fellows. The Fellows Programs bestows honorary recognition upon AASLD Regular and International members who have made a significant contribution to the knowledge and/or practice of liver and biliary diseases, and are considered leaders in the

Alexandria, VA – [March 18, 2025] – The American Association for the Study of Liver Diseases ( AASLD ) is inviting members to apply, for their sites, to participate in the TARGET-LD Study which broadly studies outcomes for patients with chronic liver disease (CLD) and cirrhosis. This unique opportunity allows members to apply to join the largest, most comprehensive, and technologically advanced

AASLD is excited to announce another opportunity to share your liver research at Digestive Disease Week® (DDW) 2025! DDW is now accepting clinical and basic science Late-Breaking Abstract submissions through Wednesday, March 5. Submissions should feature newsworthy, high-impact data that was not available by the general submission deadline. This is your chance to present groundbreaking findings

ALEXANDRIA, Virginia (January 31, 2025) — The American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS) are pleased to announce the appointment of the next Editors-in-Chief for Liver Transplantation , Dr. Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD, Hospital Clinic, University of Barcelona, Spain and Dr. Timucin Taner, MD, PhD, Mayo

Julie Deal Announces Retirement AASLD executive served the society for more than two decades ALEXANDRIA, Virginia (Dec. 20, 2024) — The American Association for the Study of Liver Diseases (AASLD) has announced that Deputy CEO and AASLD Foundation Executive Director Julie Deal will be retiring after 25 years of service to the organization. During her tenure with AASLD, Julie has contributed to

Embargoed Until Monday, Nov. 18, 2024, 12:01 a.m. EST Contact: Beth Casteel, 703-300-3803 bcasteel@thereisgroup.com Updated Model Reduces Liver Transplant Disparities for Women Transplant rates and waitlist deaths for women now similar to men SAN DIEGO, California (Nov. 18, 2024) — Since the adoption of a newmodel for assessing the severity of liver disease, women are more likely to be added to

Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver Diseases Company announces 600,000+ patient enrollment milestone in TARGET-LD Durham, NC – [Date ASAP] - Target RWE , real-world evidence leader, today shared updates from its strategic partnership with AASLD to support the Cirrhosis

Embargoed Until Wednesday, Nov. 13, 2024, 12:01 a.m. EST Contact: Beth Casteel, 703-300-3803 bcasteel@thereisgroup.com Beer-Only Drinkers’ Diets are Worse Than Wine Drinkers As obesity, alcohol use and liver disease rise, physicians should note habits SAN DIEGO, California (Nov. 13, 2024) — Beer drinkers have lower-quality diets, are less active, and are more likely to smoke cigarettes than people

Embargoed Until Saturday, Nov. 16, 2024, 12:01 a.m. ET Contact: Beth Casteel, 703-300-3803 bcasteel@thereisgroup.com AI Finds Undiagnosed Liver Disease in Early Stages 83% of patients who met MASLD criteria were not diagnosed SAN DIEGO, California (Nov. 16, 2024) — Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a recent study revealed that an

EMBARGOED FOR RELEASE Friday, November 15, 2024, 7 p.m. PDT Contact: Beth Casteel, 703-300-3803 bcasteel@thereisgroup.com AASLD Foundation Receives Transformational $25 Million Gift R. Todd Stravitz Research Fund to bolster growth in early-career liver disease research SAN DIEGO, California (Nov. 15, 2024) — The American Association for the Study of Liver Diseases (AASLD) Foundation has received a